62 results about "Quinazolinone" patented technology

The invention relates to the field of organic chemical synthesis, in particular to a quinazolinone compound synthesized by carbon dioxide and a preparation method of the quinazolinone compound. According to the preparation method for synthesizing the quinazolinone compound from carbon dioxide, carbon dioxide, a 2-aminobenzamide compound and aryl halide are taken as raw materials, and are subjected to a heating reaction in the presence of a palladium metal catalyst, a ligand, a reducing agent, alkali and an organic solvent to generate the quinazolinone compound. The mechanism is as follows: carbon dioxide forms an intermediate A under the conditions of alkali and a reducing agent, aryl halide and the intermediate A form a carbonyl metal compound B under the action of a palladium metal catalyst, and then the carbonyl metal compound B reacts with a 2-aminobenzamide compound under the action of the alkali and the reducing agent to obtain the quinazolinone compound. The catalyst system has universality to various types of 2-aminobenzamide and derivatives and aryl halides thereof, the raw materials are wide in source, cheap and easy to obtain, and the reaction process is simple and controllable.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

This application relates to the field of organic chemical synthesis, specifically to a method for synthesizing quinazolinone compounds from carbon dioxide and its preparation. The method uses carbon dioxide, 2-aminobenzamide compounds, and aryl halides as raw materials, and reacts under heating in the presence of a palladium metal catalyst, a ligand, a reducing agent, a base, and an organic solvent to generate quinazolinone compounds. The mechanism is as follows: carbon dioxide forms intermediate A under alkaline and reducing conditions; the aryl halide reacts with intermediate A under the action of a palladium metal catalyst to form a carbonyl metal compound B, which then reacts with the 2-aminobenzamide compound under the action of an alkaline and reducing agent to obtain the quinazolinone compound. This catalyst system is universally applicable to various types of 2-aminobenzamides and their derivatives, as well as aryl halides; the raw materials are widely available, inexpensive, and readily available; and the reaction process is simple and controllable.

The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

The invention belongs to the technical field of preparation of quinazolinone. The invention provides a method for preparing butene substituted quinazoline-4 (3H)-ketone, which is characterized in that a spiro-2, 3-dihydroquinazoline-4 (1H)-ketone compound, sodium bicarbonate, 4DPAIPN and dimethyl sulfoxide are subjected to a reaction together. According to the method provided by the invention, additional addition of a metal catalyst, a ligand and an additional oxidant is not needed, reaction conditions are relatively mild, an operation process is relatively simple and convenient, post-treatment is relatively easy, side reactions possibly caused under high temperature and strong oxidation conditions can be reduced, and potential problems caused by metal residues and use of the oxidant are reduced.

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

This invention discloses a method for preparing a bis(trifluoromethyl)quinazolinone amide derivative, comprising the following steps: under nitrogen protection, intermediate A is activated using an alkaline reagent, and then an acylation reagent is added to react and obtain the target compound. By innovatively utilizing a precise ratio system of bis(trimethyl)silylamine lithium (LiHMDS) and acetic anhydride, and conducting the reaction under low-temperature conditions, the acylation step can be completed in only 1-5 minutes, significantly shortening the overall process cycle compared to traditional methods and greatly improving production efficiency.

The invention discloses a synthesis method of a 2-position amide substituted quinazolinone derivative, which is characterized in that anthranilamide and pyruvoamide are used as raw materials, under the condition that N, N-dimethylformamide is used as a solvent, iodine is used as a catalyst, and various amide-containing quinazolinone derivatives with different substituent groups are conveniently and quickly prepared. The method is wide in substrate compatibility, mild in reaction condition, easy to operate, simple in post-treatment and suitable for industrial production.

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP / TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP / TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

A compound of general formula (I) and also the stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salts thereof, and also to the use thereof for the prevention and / or treatment of disorders caused by intracellularly acting toxins using retrograde transport, or by viruses or bacteria using retrograde and / or syntaxin 5-dependent transport to infect cells.

The invention discloses a method for synthesizing 2, 3-disubstituted quinazolinone based on NHC-palladium catalytic oxidative coupling. A methyl anthranilate derivative, a non-tert-butyl isocyanide derivative and an arylboronic acid derivative are taken as substrates, the molar ratio is 0.5: 1.2: 1.0, a reaction is performed for 24 hours in a sealed tube at the temperature of 100 DEG C under the protection of nitrogen in an NHC-palladium catalyst, a copper acetate oxidizing agent and a DMF (Dimethyl Formamide) solvent, and a product is obtained through silica gel column chromatography purification. The method solves the problems of narrow substrate, low atom economy and the like in the prior art, is compatible with electron donating / withdrawing and halogen groups, has the yield of 47-97% and mild conditions, and is suitable for efficient synthesis of active heterocyclic compounds in the field of medicines.

The invention discloses an acylhydrazone compound containing a quinazolinone fragment as well as a preparation method and application thereof, and relates to the technical field of medicinal chemistry, the acylhydrazone compound containing the quinazolinone fragment or pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form and prodrug of the acylhydrazone compound, and the structural formula of the acylhydrazone compound containing the quinazolinone fragment or pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form and prodrug of the acylhydrazone compound containing the quinazolinone fragment is shown in the specification. According to the invention, acylhydrazone compounds containing quinazolinone fragments are designed and synthesized by utilizing a splicing principle, the compounds are subjected to anticancer activity test, and the compounds with anticancer activity superior to that of 5-fluorouracil are screened out from the acylhydrazone compounds.

The invention relates to a synthetic method of an indoloquinazolinone compound. The synthetic method comprises the following steps: reacting 2-aminoacetophenone with aryl isocyanate under the catalytic action of a palladium complex to obtain the indoloquinazolinone compound, wherein the palladium complex is an N, N-coordinated palladium complex containing a meta-carborane ligand. The preparation process of the palladium complex comprises the following steps: adding an n-BuLi solution into a meta-carborane solution to carry out a deprotonation reaction, then adding 3-chloromethylpyridine to carry out a nucleophilic substitution reaction, finally adding Pd (OAc) 2 to carry out a coordination reaction to obtain a palladium complex head product, and carrying out post-treatment to obtain the palladium complex product. Compared with the prior art, the method disclosed by the invention has the advantages of good adaptability, high catalytic efficiency, few byproducts, mild reaction conditions, lower cost, easiness in product separation, no generation of a large amount of waste residues and the like.

The invention relates to application of a polycyclic quinazolinone compound in resisting plant pathogenic fungi in the technical field of organic synthetic chemistry and agricultural pharmacology, the structural formula of the derivative is shown as I or II, in the structural formula, R is H, 4-OMe, 4-Me, 4-CO2Me, 4-F, 4-CF3, 4-Cl, 4-Br, 2-Br or 2-F, and R is H, 4-OMe, 4-Me, 4-CO2Me, 4-F, 4-CF3, 4-Cl, 4-Br, 2-Br or 2-F; the series of compounds have a certain inhibition effect on plant pathogenic fungi including strawberry botrytis cinerea, fusarium graminearum, rhizoctonia solani and magnaporthe oryzae, and can be applied to plant protection as a bactericide. The preparation method comprises the following steps: by taking N-cyanamide olefin as a raw material and lauroyl peroxide as an oxidizing agent, reacting in a dichloromethane or trichloromethane solvent at 80-120 DEG C to obtain the polycyclic quinazolinone compound with antibacterial activity. The preparation method is simple to operate, green and efficient.

The application belongs to the field of chemical industry, and particularly relates to a synthesis method of a substituted pyrazoloquinazoline derivative. The method provided by the application comprises sequentially preparing 2-chloro-5,6,7,8-tetrahydroquinazoline, 2-chloro-6,7-dihydroquinazolin-8(5H)-ketoxime, 2-chloro-6,7-dihydroquinazolin-8(5H)-ketone, 2-(2-methoxy-8-oxo-5,6,7,8-tetrahydroquinazolin-7-yl)-2-oxoacetic acid methyl ester and 1-(2-hydroxyethyl)-8-methoxy-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid methyl ester, and finally obtaining 1-(2-hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide. By using the method of the application, three reaction steps are reduced, the total yield is increased by nearly one time, and the method is far higher than the original process route; and the application of dangerous reagents such as hydrazine hydrate and iodine is avoided, and the method is easy to scale up.

The application discloses a 2,3-dihydroquinazolinone compound and a preparation method and application thereof. A substituted 3-(but-3-en-1-yl)quinazolin-4(3H)-one of formula 1 is subjected to chemical reaction under reaction conditions to obtain a 2,3-dihydroquinazolinone compound with different substituents of formula 2; or a substituted N-cyano-N-[(1-vinyl-2-yl)phenyl]benzamide of formula 3 is subjected to chemical reaction under reaction conditions to obtain a 2,3-dihydroquinazolinone compound with different substituents of formula 4; the disclosed synthesis method is simple, safe and low in reaction cost. Moreover, the 2,3-dihydroquinazolinone compound prepared by the method has excellent inhibitory activity on tumor cells.

This invention discloses a visible light-induced method for synthesizing α,β-unsaturated acetylide amides, belonging to the field of organic synthesis. The invention constructs a visible light-responsive aromatization-driven carbamoyl radical precursor—a dihydroquinazolinone derivative precursor containing a carbamoyl segment. Under direct visible light irradiation, a single-electron process is triggered, leading to C-C bond cleavage and aromatization, thereby efficiently releasing a carbamoyl radical in situ. Subsequently, this radical undergoes selective acetylation transfer and coupling with an acetylation-based high-valent iodine reagent, achieving the rapid construction of the target α,β-unsaturated acetylide amide. This process can be completed via a one-pot pathway of "visible light direct-driven—radical generation—acetylation transfer / coupling," avoiding the introduction of additional photocatalysts, making the reaction system simpler, the cost more controllable, and the post-processing more convenient.

The application provides a 4-quinazolinone derivative containing a benzene sulfonamide piperazine ketone and a preparation method and application thereof. The derivative has the structure shown in the following general formula I. The application further relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / HIV-2 capsid protein regulator in preparation of an anti-AIDS drug.

The invention belongs to the field of pesticides, and discloses a compound with a structure as shown in a formula I. A preparation method of the compound comprises the following steps: reacting anthranilic acid with formamide, and then reacting with 1, 4-dibromobutane under the action of sodium hydride to obtain 3-(4-bromobutyl) quinazoline-4 (3H)-ketone; then, phenylacetic acid sequentially reacts with methyl alcohol, hydrazine hydrate, potassium hydroxide, carbon disulfide and 3-(4-bromobutyl) quinazoline-4 (3H)-ketone, and the quinazolinone derivative containing the oxadiazole unit is obtained. The quinazolinone derivative containing the oxadiazole unit is a novel compound, has an inhibiting effect on fusarium graminearum, rhizoctonia solani and botrytis cinerea, and can be used for preventing and treating plant diseases caused by fungi.

The invention relates to the technical field of chemical synthesis of medicines, and particularly discloses a production and preparation method of an erlotinib intermediate. The method comprises the following steps: taking 3, 4-dihydroxy benzaldehyde as an initial raw material, sequentially carrying out etherification, oxidation and nitration reactions to prepare 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid, finally dissolving the 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid, formamide, formic acid and triethylamine in gamma-valerolactone to form two material flows, and carrying out heat treatment to obtain the 2-nitro-4, 5-bis (2-methoxyethoxy) benzoic acid. And carrying out continuous cyclization reaction in a fixed bed reactor filled with a specific composite catalyst, and carrying out post-treatment to obtain the target product 6, 7-bis (2-methoxyethoxy)-4-quinazolinone. According to the method, the raw materials are easy to obtain, the reaction efficiency and the product purity are remarkably improved by optimizing the synthesis route and the reaction conditions, and a novel efficient, environment-friendly and stable method is provided for large-scale production of the erlotinib key intermediate.

The invention relates to a pyrrolo [2, 1-b] quinazoline-9 (1H)-ketone derivative and application thereof. The invention discloses a method for synthesizing pyrrolo [2, 1-b] quinazoline-9 (1H)-ketone based on cyclization reaction of 2-(phenylethynyl) quinazoline-4 (3H)-ketone and nitrostyrene and application of the pyrrolo [2, 1-b] quinazoline-9 (1H)-ketone, and belongs to the field of organic synthetic chemistry and medicinal chemistry. The synthesis method is realized through a 3 + 2 cyclization reaction of 2-(phenylethynyl) quinazoline-4 (3H)-ketone and nitrostyrene under base catalysis, the reaction condition is mild, the yield is good, and large-scale preparation is easy. The newly synthesized compound has obvious proliferation inhibition activity on various tumor cells such as gastric cancer, liver cancer, breast cancer, lung cancer, colon cancer, cervical cancer and the like, and can be used as a lead compound of an anti-tumor drug for preparing a novel anti-tumor drug.

The present invention provides a compound that has DYRK-inhibiting activity and that is useful as a drug. Specifically, the present invention provides a dihydroquinazolinone derivative represented by formula (I) (in the formula, R1, R2, R3, R4, R5, and Q are as defined in the description), or a pharmaceutically acceptable salt thereof.

The invention discloses a quinazolinone compound as well as a preparation method, a pharmaceutical composition and application thereof, and relates to the technical field of pharmaceutical chemistry. In particular to quinazolinone compounds as shown in formulas I and II or pharmaceutically acceptable salts, prodrugs, stereoisomers, diastereoisomers, enantiomers, tautomers, solvates, salts of the solvates, polymorphic substances and isotope labeling compounds of the quinazolinone compounds. . The quinazolinone compound designed and synthesized by the invention can effectively inhibit the activity of PDE1C protein, the IC50 value of the preferable compound can reach the micromolar concentration level, an excellent curative effect is achieved on the molecular level, and the application prospect is very wide.

The application discloses a preparation method of a Silverton type uranium molybdenum oxygen cluster and application of the Silverton type uranium molybdenum oxygen cluster in catalytic synthesis of quinazolinone, and belongs to the technical field of polyacid chemistry and catalytic chemistry. 24 The method is to dissolve Fe2(SO4)3 or CoSO4.7H2O or NiSO4.7H2O and (NH4)6Mo7O The Silverton type uranium molybdenum oxygen cluster has high stability and can keep stable in aqueous solutions with pH values of 1-13 and various organic solvents; the Silverton type uranium molybdenum oxygen cluster exhibits excellent catalytic activity in a reaction of synthesizing quinazolinone compounds by dehydration condensation of o-aminobenzamide compounds and aldehyde compounds, and the yield of a target product is as high as 93%. The preparation method of the Silverton type uranium molybdenum oxygen cluster is simple, the Silverton type uranium molybdenum oxygen cluster has high stability and good catalytic activity, the method provides a reference for structure research of uranium-containing poly-molybdenum oxygen clusters, and has a good application prospect in the field of catalytic chemistry.

Compounds having Structure I are provided for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in particular for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds having Structure I are capable of increasing the level of adipose triglyceride lipase (ATGL). Also provided is the process of preparing compounds having Structure I.

The application discloses a synthesis method of 4-trifluoroethyl-2-quinozolinone compound and belongs to the field of organic chemistry. The method can quickly realize one-pot synthesis of 4-trifluoroethyl-2-quinozolinone compound under blue light irradiation by using a novel trifluoromethyl copper complex, an ortho alkenyl aryl urea compound, potassium carbonate and potassium persulfate as reactants. The method has wide substrate applicability, simple raw materials and low economic cost. In addition, the method realizes synthesis of the target product, does not need to add a catalyst for catalysis, and can obtain the target product in a good yield only by reacting for 12 hours. The target compound has wide application in the fields of medicines, pesticides and the like.

The application discloses a selective inhibitor for BRCA mutation and application thereof. Specifically, the application relates to a quinazolinone compound shown in a general formula (I) or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound has better selectivity for BRCA mutation, has a good inhibition rate on the proliferation of BRCA mutant cells at a low concentration, and is superior to existing olaparib and AZD5305 and the like. Through a nude mouse tumorigenesis experiment, it is proved that the drug obviously shows an inhibitory effect on tumor growth at a low drug concentration, and has no obvious toxic side effects.

This invention discloses an acylhydrazone compound containing a quinazolinone fragment, its preparation method, and its application, relating to the field of medicinal chemistry. The acylhydrazone compound containing the quinazolinone fragment, or its pharmaceutically acceptable salt, isomer, hydrate, solvate, crystal form, or prodrug, has the following structural formula. This invention designs and synthesizes acylhydrazone compounds containing a quinazolinone fragment using the principle of combination, and tests these compounds on their anticancer activity, screening out compounds with anticancer activity superior to 5-fluorouracil.

The invention discloses a high-elastic breathable antifouling sofa cover and a preparation method thereof, and relates to the technical field of sofa covers. R-3-butene-2-amino alcohol, maleic anhydride, sodium hydrogen sulfite and phosgene are subjected to a reaction to be formed, then grafted to the surface of hemp cotton yarn and polymerized with 4, 6-octadienoic acid and 1, 2-difluoro-3-(propyl-2-ene-1-yl) benzene, a surface hydrophilic and external hydrophobic structure is constructed, the surface energy of the sofa cover is reduced, the water resistance and oil resistance of the sofa cover are improved, and meanwhile the sofa cover has the advantages of being good in water resistance and oil resistance. The anti-static effect is improved, dust adsorption is reduced, complexation with silver ions is achieved, and the anti-fouling effect of the sofa cover is enhanced; 2-aminocaproic acid, 2-amino-3, 5-dimethylbenzoyl chloride, 2-chloroacetyl chloride and dioctyl methylamine are utilized to modify cotton yarns, quinazolinone and quaternary ammonium structures are introduced to the surfaces of fibers to synergistically inhibit the growth of bacteria and improve the antibacterial effect of the sofa cover, then the modified hemp cotton yarns are used as camlet, the modified cotton yarns are used as core yarns, and the sofa cover is prepared by twisting and spinning.